CA1281288C - Tumor therapy - Google Patents

Tumor therapy

Info

Publication number
CA1281288C
CA1281288C CA000493821A CA493821A CA1281288C CA 1281288 C CA1281288 C CA 1281288C CA 000493821 A CA000493821 A CA 000493821A CA 493821 A CA493821 A CA 493821A CA 1281288 C CA1281288 C CA 1281288C
Authority
CA
Canada
Prior art keywords
proline
amino acids
hydroxy
cis
hydroxyproline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA000493821A
Other languages
French (fr)
Inventor
Wilhelm Hoerrmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of CA1281288C publication Critical patent/CA1281288C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Abstract Tumor Therapy.
This invention relates to a new therapy for cancer, blood vessel- and viral dideases by administering Hydroxy - prolin and additional compounds.

Description

Description:
The main subject of this application is a new therapy for cancer especially carcinomas and related tumors. The expression "related tumors" means tumors which are like carcinomas of an embryologically epithelial origin. Examples are astrocytomas, neurinomas, suprarenal (medulla) tumors and so on.
In the years 1933 - 1946 Helen M. Dyer of the United States National Cancer Institute administered a wide range of amino acids in experimen-tal tumors of the ~ . Among others she mentioned hydroxyproline, but it is known that results of experimental animal tumors are scarcely transferable to human cancer.
In the last about 20 years electronmicroscopic device have shown the existence of the so called cytoskeleton within the ce71s. Immunolo-gical methods applied on the cytoskeleton are today used to recognize the origin of a cancer in their metastases. Applicant's concept, however, goes farther and postulates that a disturbance of the cytoske-leton is an essential factor for the pathogenesis of cancer, especially carcinomas. When in cancer cells and tissues the cytoskeleton, the cell junctions, the basal laminas and the filaments of the extra-cellular matrix, the connective tissues additionally are out of order it is doubtless indicated to substitute the constituents of these filamental systems which are specific amino acids.
From this point of view one of the most important of these amino acids is hydroxyproline. Here, however, it is not sufficient to differentiate between L and D configuration as Dyer had done. The decisive act is to differentiate also between cis and trans isomers of hydroxyproline which arise of the asymmetrical nature of the hydroxyl-group bearing carbon atom (this carbon atom is preferably number 49 but also number 3 is to be considered).

: ' 1 The proof that that is so was established by tests which were performed according to applicants suggestion. These were not tests on experimental animal tumors which are scarcely trans-ferable in their results to native human cancer. They were performed in human cell culture, the cells of which were re-moved from brain tumor patient by neurosurgery. The administe-ring of L - 4 - cis - Hydroxyproline to these astrocytoma tumor cells brought about not only a considerably slowed rate of cell division but also induced morphological redifferentia-tion, that is the cells resembled no longer tumor but normal astroglial cells. On the other side the trans isomer of L - 4 -Hydroxyproline showed not at all any positive effects.

Hydroxyproline may be given alone or combined with other amino acids which are occuring in the above named filamental system as there are proline, valine, alanine, lysine, hydroxylysine, glycine, cysteine and cystine.

The administration of such compounds however is not restricted to cancer cases alone, but is also indicated in cases of viral infection and blood vessels disease. Even neurological and rheumatological indications are marking out.

The administering of amino acids in their free form is a pos-sible method. Their specific effect however can also be brought into existence by administering compounds containing these amino acids that is for examples in acetylated form or as correspon-ding peptides. That means the administering of the named amino acids can be directly or indirectly.

Amino acids are scarcely toxic at all, therefore the named com-pounds have a wide doses range. However as with all amino acids therapy the known contraindications should wherever possible be excluded, especially patients with renal diseases.

The therapeutic administering of these compounds is principally the same as with all amino acid therapy. Tabletts or dragees for oral, solutions for intravenous (or central intravenous) administering.
Dosis range for hydroxyproline 0,01 - 0,1 g/kg daily in severe cases up to 0,2 g/kg.
Dosis range for hydroxyproline combined with proline, valine, alanine, lysine, hydroxylysine and glycine is for hydroxyproline 0,006 0,06 and 0,003 - 0,03 for each of the other amino acid.

Claims

Claim 1 Use of cis-4-hydroxy-L-proline in the preparation of a medicament for the treatment of carcinoma.
or related tumors.
Claim 2 Use of cis-3-hydroxy-L-proline in the preparation of a medicament for the treatment of carcinomas or related tumors.
Claim 3 Use of cis-4-hydroxy-L-proline in the preparation of a medicament according to Claim 1, the me-dicament also comprising the amino acids proline, valine, alanine, lysine, hydroxylysine, glycine, cycteine and systine.
Claim 4 Use of cis-3-hydroxy-L-proline in the preparation of a medicament, according to Claim 2, the me-dicament also comprising the amino acids proline, valine, alanine, lysine, hydroxylysine, glycine, cycteine and cystine.
CA000493821A 1984-11-05 1985-10-24 Tumor therapy Expired - Lifetime CA1281288C (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US66820084A 1984-11-05 1984-11-05
US06/668,200 1984-11-05
US72356585A 1985-04-15 1985-04-15
US06/723,565 1985-04-15

Publications (1)

Publication Number Publication Date
CA1281288C true CA1281288C (en) 1991-03-12

Family

ID=27099851

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000493821A Expired - Lifetime CA1281288C (en) 1984-11-05 1985-10-24 Tumor therapy

Country Status (5)

Country Link
JP (1) JPH0723309B2 (en)
CA (1) CA1281288C (en)
CH (1) CH667591A5 (en)
DE (1) DE3538619C2 (en)
GB (1) GB2171302B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987004925A1 (en) * 1986-02-18 1987-08-27 Biota Scientific Management Pty. Ltd. Stimulation of angiogenesis
DE3728852C2 (en) * 1987-08-28 2003-06-18 Wilhelm Hoerrmann Medicines for tumor therapy
EP0307390A3 (en) * 1987-09-04 1991-04-10 Merckle Gmbh Chemical compound consisting of cis-3-hydroxyproline for therapeutic treatment, and process for its preparation
US5827874A (en) * 1995-05-05 1998-10-27 Meyer; Hans Methods of treating pain and inflammation with proline
WO1997033578A1 (en) * 1996-03-11 1997-09-18 Wilhelm Hoerrmann Combination of cis-4-hydroxy-l-proline and n-methyl-cis-4-hydroxy-l-proline for use as a therapeutic agent, in particular in cancer treatment
WO1997038690A1 (en) * 1996-04-16 1997-10-23 Chephasaar Chem.-Pharm. Fabrik Gmbh Agent for inhibiting leukocyte invasion of tissues
DE10359828A1 (en) * 2003-12-12 2005-07-28 Zoser B. Dr.Rer.Nat. Salama CHP gemcitabine combination agents and their use as antitumor agents, in particular anti-metastatic agents
DE10359829A1 (en) * 2003-12-12 2005-07-21 Salama, Zoser B., Dr.Rer.Nat. Use of CHP as inhibitor of glutathione-S-transferases and collagen IV
UA82753C2 (en) * 2003-12-18 2008-05-12 Цозер Б. Салама Proline derivatives used as pharmaceutical active ingredients for the treatment of tumours
RU2007101074A (en) * 2004-06-14 2008-07-20 Зозер Б. САЛАМА (DE) PHARMACEUTICAL ANTICANCER COMPOSITION PROLINE OR ITS DERIVATIVES AND ANTITUM ANTIBODY
WO2007059047A2 (en) 2005-11-11 2007-05-24 Chandran V Ravi Acetylated amino acids as anti-platelet agents, nutritional and vitamin supplements

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932638A (en) * 1967-09-14 1976-01-13 Franco-Chimie S.A.R.L. Compositions and methods for wound healing
FR7639M (en) * 1967-09-14 1970-02-02
GB1399887A (en) * 1971-06-10 1975-07-02 Prockop D J Composition and methods for controlling collagen synthesis
FR2207702B1 (en) * 1972-11-23 1975-11-28 Rhone Poulenc Ind
JPS59164718A (en) * 1983-03-10 1984-09-17 Advance Res & Dev Co Ltd Preventive for cancer

Also Published As

Publication number Publication date
DE3538619C2 (en) 1995-11-09
DE3538619A1 (en) 1986-05-07
JPS61155324A (en) 1986-07-15
GB8527159D0 (en) 1985-12-11
GB2171302B (en) 1989-08-23
JPH0723309B2 (en) 1995-03-15
CH667591A5 (en) 1988-10-31
GB2171302A (en) 1986-08-28

Similar Documents

Publication Publication Date Title
Huddlestone et al. Induction and kinetics of natural killer cells in humans following interferon therapy
Barranco et al. Treatment of relapsing polychondritis with dapsone
Parfrey et al. Captopril-induced pemphigus.
CA1281288C (en) Tumor therapy
ATE185268T1 (en) ADVANCED DRUG DELIVERY SYSTEM AND METHOD FOR TREATING PSYCHIATRIC, NEUROLOGICAL AND OTHER DISEASES WITH CARBAMAZEPINE
Palmour et al. Characterization of a peptide from the serum of psychotic patients
CA2204147A1 (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US5200395A (en) Pharmaceutical composition of BUF-5 for treating anemia
Kornfeld et al. Metabolism of 14C‐labeled pyridostigmine in myasthenia gravis: Evidence for multiple metabolites
Kawakita et al. Characterization of human megakaryocyte colony-stimulating factor in the urinary extracts from patients with aplastic anemia and idiopathic thrombocytopenic purpura
Guilhou et al. Somatostatin treatment of psoriasis
JP4463885B2 (en) Fulminant hepatitis disease treatment
Konturek Comparison of pancreatic responses to natural and synthetic secretins in conscious cats
Jones et al. Neutrophil accumulation in vivo following the administration of chemotactic factors
Crockett et al. Side effects and toxicity of interferon in the treatment of recurrent respiratory papillomatosis
Grójec et al. Effect of staphylococcal leukocidin on mouse leukocyte system
Plager The induction of transient increases in mitotic rate in murine tissues following prolonged intravenous infusions of hydroxyurea
Chen et al. Recurrent agranulocytosis induced by two different antithyroid agents
Türker et al. High degree of conversion of angiotensin I to angiotensin II in the mesenteric circulation of the isolated perfused terminal ileum of the cat
DE3650368D1 (en) Use of Depogen to treat restricted blood circulation.
Lee et al. The incorporation of 2-[14C] glycine into porcine lens protein
US3885030A (en) Medicine comprising lysine by-products
Akmal et al. Intact and carboxyterminal PTH do not cross the blood-cerebrospinal fluid barrier
Woods Susceptibility to experimental pyelonephritis when hormonal hypertension is prevented by hypotensive drugs
Masucci et al. Clinical evaluation of “quantitative” rheoencephalography

Legal Events

Date Code Title Description
MKLA Lapsed
MKEC Expiry (correction)

Effective date: 20121205